Research Topic: psilocybin

Psilocybin-assisted massed cognitive processing therapy for chronic posttraumatic stress disorder: Protocol for an open-label pilot feasibility trial

mycolabadmin

This study tests whether psilocybin (a psychedelic compound) combined with intensive therapy can help treat chronic PTSD better than therapy alone. Fifteen patients with PTSD will receive one dose of psilocybin alongside 12 therapy sessions completed over a single week. Researchers will track feasibility, safety, symptom improvements, and use wearable devices to monitor physiological changes. The results will help determine whether larger trials should test this innovative combination therapy.

Read More »

Attitudes toward psychedelics and psychedelic-assisted therapy among potential mental health service users and the general population in Australia

mycolabadmin

This Australian study surveyed over 500 people about their views on psychedelics like psilocybin and MDMA for treating mental health conditions. Most people supported medical legalization of these substances, though many had safety concerns. Those with mental illness, those with prior psychedelic experience, and those with better knowledge of psychedelics were most supportive of their therapeutic use.

Read More »

Lower-dose psycholytic therapy – A neglected approach

mycolabadmin

This review examines psycholytic therapy, a method using lower doses of LSD or psilocybin combined with ongoing psychotherapy to help people process psychological conflicts and trauma. Developed in Europe during the 1960s-1970s and used successfully at over 30 clinics, this approach was largely abandoned when psychedelics became illegal but is now being reconsidered. Historical research shows it was effective for anxiety, depression, and personality issues in treatment-resistant patients, with safety profiles comparable to conventional therapy.

Read More »

Striking long-term beneficial effects of single dose psilocybin and psychedelic mushroom extract in the SAPAP3 rodent model of OCD-like excessive self-grooming

mycolabadmin

Researchers tested whether psilocybin (the active compound in magic mushrooms) could treat obsessive-compulsive disorder using genetically modified mice that exhibit excessive grooming similar to OCD in humans. A single dose of psilocybin or psychedelic mushroom extract significantly reduced the excessive grooming behavior and anxiety in these mice, with benefits lasting up to six weeks. These findings suggest psilocybin may be a promising new treatment for OCD in humans, offering longer-lasting effects from a single dose compared to current medications.

Read More »

Exploring Psilocybe spp. mycelium and fruiting body chemistry for potential therapeutic compounds

mycolabadmin

This study compared the chemical makeup of psilocybin mushroom mycelium (the root-like growth) versus fruiting bodies (the mushrooms themselves) to understand their different therapeutic potential. While fruiting bodies contain much higher levels of psilocybin, the psychoactive compound, mycelium accumulates other beneficial compounds like α-GPC that may enhance cognition and motor function without strong psychedelic effects. This research suggests that mushroom mycelium could be developed as a non-intoxicating therapeutic alternative with its own unique health benefits.

Read More »

Exploring Psilocybe spp. mycelium and fruiting body chemistry for potential therapeutic compounds

mycolabadmin

Scientists studied magic mushrooms at different growth stages to understand their chemical makeup. They found that mature mushroom caps contain high levels of psilocybin (the psychedelic compound) but the root-like mycelium contains different beneficial compounds like ergothioneine and choline. This suggests mycelium could be developed as a therapeutic product without the psychedelic effects, potentially offering health benefits while avoiding the mind-altering properties.

Read More »

Prospective Preference Assessment for the Psilocybin for Enhanced Analgesia in Chronic nEuropathic PAIN (PEACE-PAIN) Trial

mycolabadmin

Researchers surveyed chronic pain patients about their willingness to participate in a trial testing psilocybin (a compound from magic mushrooms) as a pain treatment. About 77% of patients were interested in participating. Interestingly, patients who had previously used psychedelics were much more willing to join the trial. Common reasons for wanting to participate included needing new pain treatments, while concerns about side effects and practical difficulties like attending multiple appointments discouraged others.

Read More »
Scroll to Top